Curtis R Chong1, Vivian J Park2, Bevin Cohen3,4, Michael A Postow5, Jedd D Wolchok5, Mini Kamboj6,7. 1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Department of Pharmacy, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Office of Nursing Research, Department of Nursing, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. School of Nursing, Columbia University Medical Center. 5. Melanoma & Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 6. Infection Control, Memorial Sloan-Kettering Cancer Center, New York, New York. 7. Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Cancer patients are at a higher risk for developing influenza (flu)- related complications. It is unclear if the flu vaccine exacerbates immune events in patients treated with immune checkpoint inhibitors (ICIs). METHODS: We conducted an institutional review board-IRB-approved retrospective review of advanced cancer patients on ICIs who received the flu vaccine during three 3 consecutive seasons: 2014-2015, 2015-2016, and 2016-2017. The primary outcome assessed was any "new onset" immune-related adverse event (IRAE). A subset analysis of vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1) agents (nivolumab or pembrolizumab) was conducted to assess overall IRAE rates for comparison with published clinical trials. RESULTS: During the three 3 seasons, 370 patients met criteria for ICI and vaccination within ~ twoapproximately 2 months (65 days). The most common underlying cancers were lung (46%) and melanoma (19%); 61% of patients received an anti-PD-1 agent only. In the entire cohort, 20% experienced an IRAE (any grade); incidence of grade 3 or 4 toxicity was 8%. No grade 5 events occurred. In the subset of 170 patients newly treated with anti-PD-1 agents, the overall IRAE rate was 18% and, grade 3/4 events occurred in 7.6%. Influenza was diagnosed in 2 patients. CONCLUSIONS: No increase in incidence or severity of IRAEs was detected in patients on ICIs who received the inactivated influenza vaccine within ~ approximately 2 months of ICI. For newly treated patients on anti-PDI-1 agents, IRAE rates were comparable to those from published clinical trials and did not vary with order of administration. Routine seasonal flu vaccination is encouraged in patients on ICIs.
BACKGROUND:Cancerpatients are at a higher risk for developing influenza (flu)- related complications. It is unclear if the flu vaccine exacerbates immune events in patients treated with immune checkpoint inhibitors (ICIs). METHODS: We conducted an institutional review board-IRB-approved retrospective review of advanced cancerpatients on ICIs who received the flu vaccine during three 3 consecutive seasons: 2014-2015, 2015-2016, and 2016-2017. The primary outcome assessed was any "new onset" immune-related adverse event (IRAE). A subset analysis of vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1) agents (nivolumab or pembrolizumab) was conducted to assess overall IRAE rates for comparison with published clinical trials. RESULTS: During the three 3 seasons, 370 patients met criteria for ICI and vaccination within ~ twoapproximately 2 months (65 days). The most common underlying cancers were lung (46%) and melanoma (19%); 61% of patients received an anti-PD-1 agent only. In the entire cohort, 20% experienced an IRAE (any grade); incidence of grade 3 or 4 toxicity was 8%. No grade 5 events occurred. In the subset of 170 patients newly treated with anti-PD-1 agents, the overall IRAE rate was 18% and, grade 3/4 events occurred in 7.6%. Influenza was diagnosed in 2 patients. CONCLUSIONS: No increase in incidence or severity of IRAEs was detected in patients on ICIs who received the inactivated influenza vaccine within ~ approximately 2 months of ICI. For newly treated patients on anti-PDI-1 agents, IRAE rates were comparable to those from published clinical trials and did not vary with order of administration. Routine seasonal flu vaccination is encouraged in patients on ICIs.
Authors: Jeffrey S Weber; Omid Hamid; Scott D Chasalow; Dianna Y Wu; Susan M Parker; Susan Galbraith; Sacha Gnjatic; David Berman Journal: J Immunother Date: 2012-01 Impact factor: 4.456
Authors: Ahmed Taha; Inbal Vinograd; Ali Sakhnini; Noa Eliakim-Raz; Laura Farbman; Rina Baslo; Salomon M Stemmer; Anat Gafter-Gvili; Leonard Leibovici; Mical Paul Journal: J Infect Date: 2014-10-22 Impact factor: 6.072
Authors: Catherine D Cooksley; Elenir B C Avritscher; Benjamin N Bekele; Kenneth V Rolston; Jane M Geraci; Linda S Elting Journal: Cancer Date: 2005-08-01 Impact factor: 6.860
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Inbal Vinograd; Noa Eliakim-Raz; Laura Farbman; Rina Baslo; Ahmed Taha; Ali Sakhnini; Adi Lador; Salomon M Stemmer; Anat Gafter-Gvili; Leonard Leibovici; Mical Paul Journal: Cancer Date: 2013-09-16 Impact factor: 6.860
Authors: Adam C Finnefrock; Aimin Tang; Fengsheng Li; Daniel C Freed; Meizhen Feng; Kara S Cox; Kara J Sykes; James P Guare; Michael D Miller; David B Olsen; Daria J Hazuda; John W Shiver; Danilo R Casimiro; Tong-Ming Fu Journal: J Immunol Date: 2009-01-15 Impact factor: 5.422
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan Journal: MMWR Recomm Rep Date: 2018-08-24
Authors: Ramin Sedaghat Herati; David A Knorr; Laura A Vella; Luisa Victoria Silva; Lakshmi Chilukuri; Sokratis A Apostolidis; Alexander C Huang; Alexander Muselman; Sasikanth Manne; Oliva Kuthuru; Ryan P Staupe; Sharon A Adamski; Senthil Kannan; Raj K Kurupati; Hildegund C J Ertl; Jeffrey L Wong; Stylianos Bournazos; Suzanne McGettigan; Lynn M Schuchter; Ritesh R Kotecha; Samuel A Funt; Martin H Voss; Robert J Motzer; Chung-Han Lee; Dean F Bajorin; Tara C Mitchell; Jeffrey V Ravetch; E John Wherry Journal: Nat Immunol Date: 2022-07-28 Impact factor: 31.250
Authors: Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton Journal: J Immunother Cancer Date: 2021-08 Impact factor: 13.751